ABBVABBVHealthcare · Drug Manufacturers - General

ABBV Stock Forecast: AbbVie, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$286
+1.01% on the day

The 29 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $321 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 90 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$501.2B
Ticker Nerd rank
90/ 100
Median analyst target
$321
Analysts covering
29
Revenue$17.0B+10.2% y/y
Operating income$6.7B
Net income$3.6B
Free cash flow$3.1B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−0.9%
YTD
+29.1%
1Y
+28.5%
From 52W high
−2.9%
From 52W low
+47.0%
$195
$295
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
90/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Momentum
95
Value
90
Quality
89
Growth
86
Revisions
68
Accruals
64
Issuance
36

Volatility (100): The share price has been relatively steady.

Issuance (36): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ABBV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350Jan 26Apr 26Jul 26Oct 26ABBVHigh $350Median $321Low $237

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says29 analysts
23
Buy
5
Hold
1
Sell
$237
Low
$321
Median
$350
High

The green dot is the last close — the median target sits +12.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 18 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsOverweight$325 → $335
2 Nov 2026Canaccord GenuityMaintainsBuy$290 → $338
2 Nov 2026Cantor FitzgeraldMaintainsOverweight$290 → $325
2 Nov 2026GuggenheimMaintainsBuy$288 → $322
2 Nov 2026Leerink PartnersMaintainsOutperform$309 → $342
2 Nov 2026Morgan StanleyMaintainsOverweight$310 → $346
2 Nov 2026RBC CapitalMaintainsOutperform$280 → $330
2 Nov 2026UBSMaintainsNeutral$275 → $295
2 Nov 2026Wells FargoMaintainsOverweight$300 → $340
23 Oct 2026Goldman SachsMaintainsNeutral$258 → $294
21 Oct 2026BarclaysMaintainsOverweight$300 → $325
13 Oct 2026RBC CapitalReiteratesOutperform$280
9 Oct 2026GuggenheimReiteratesBuy$288
9 Oct 2026UBSMaintainsNeutral$260 → $275
8 Oct 2026Cantor FitzgeraldMaintainsOverweight$285 → $290
8 Oct 2026JP MorganMaintainsOverweight$285 → $300
7 Oct 2026Morgan StanleyMaintainsOverweight$296 → $310
6 Oct 2026ScotiabankMaintainsSector Outperform$280 → $320
10 Sept 2026HSBCMaintainsBuy$300 → $315
20 Aug 2026Piper SandlerMaintainsOverweight$298 → $303

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABBV.

Market Radar

This page is one stock. Monday covers all of them.

ABBV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ABBV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, AbbVie, Inc. returned +28.5% against +6.9% for the S&P 500, dividends included.

ABBV vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26ABBVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABBV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.2%
Analysts raising
6
Analysts cutting
18
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.6×

Cheaper than 16% of US stocks

Price / sales
7.7×

Cheaper than 14% of US stocks

Price / book
—
EV / EBITDA
18.0×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
10.3%

Higher than 54% of US stocks

Earnings growth (YoY)
2167.7%

Higher than 99% of US stocks

Gross margin
74.7%

Higher than 87% of US stocks

Operating margin
36.6%

Higher than 91% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
10.7%

Higher than 93% of US stocks

Dividend yield
2.4%

Higher than 50% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AbbVie, Inc. has a market value of $501.2B and an enterprise value of $571.8B.

  • Revenue in the twelve months to 30 June 2026: $64.4B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: $6.3B, a 9.8% net margin.

  • Diluted earnings per share, trailing twelve months: $3.54.

  • Free cash flow in the twelve months to 30 June 2026: $18.2B.

  • AbbVie, Inc. spent $1.5B on share buybacks and $12.0B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.8B.

  • Trailing P/E: 49.6×; forward P/E: 17.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.40%, paying out 117% of earnings.

  • AbbVie, Inc. employs 57,000 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ABBV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
ABBVAbbVie, Inc.$501.2B90
JNJJohnson & Johnson$651.8B86
MRKMerck & Co., Inc.$331.9B86
AMGNAmgen, Inc.$234.8B95
GILDGilead Sciences, Inc.$206.6B89
LLYEli Lilly & Co.$1.3T92
PFEPfizer Inc.$155.8B91

Take a look at ABBV’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ABBV

What is the ABBV stock price forecast for 2026-2027?

The 29 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $321, with estimates ranging from $237 to $350. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABBV stock a buy right now?

Of the 29 analysts covering AbbVie, Inc., 23 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 90 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABBV?

As at 21 Nov 2026, AbbVie, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will ABBV stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 90 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABBV stock forecast for 2030?

No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $237 to $350 over the next 12 months.

How has ABBV stock performed over the past year?

AbbVie, Inc. returned +28.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbbVie, Inc. do?

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs.

Company

About AbbVie, Inc.

AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.

CEO Mr. Robert A. Michael CPA · 57,000 employees · United States · https://www.abbvie.com